— Antimicrobial Drugs Advisory Committee of FDA scheduled for August 8, 2018 to review the Company’s NDAs for omadacycline —
— Omadacycline PDUFA action date scheduled for October 2018 —
— Company on track for a first quarter 2019 omadacycline U.S. launch —
BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based on tetracycline chemistry, today reported financial results and provided an update on financial, clinical, commercial and regulatory filing activities for the quarter ended June 30, 2018.
“With the omadacyline regulatory applications …
READ FULL TEXT